Seattle Children’s Research Institute (SCRI)

In 2018, Aptahem entered a partnership with Seattle Children’s Research Institute (SCRI) to explore the mechanisms underlying their new aptamer-based therapeutic for acute and chronic inflammatory conditions including sepsis. This work studies how the interphase of pathogen/bacteria elimination and anaphylactic shock (abrupt onset of hyper-inflammation) is affected by Apta-1.

Expanded collaborations are being discussed with SCRI for other indications within the areas inflammation and immuno therapy.